Rigel Pharmaceuticals (NASDAQ:RIGL) enrolled the first patients in its Phase 2 trial evaluating fostamatinib for the treatment of hospitalized COVID-19 patients. The study is sponsored by the NIH’s National Heart, Lung...
The FDA granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor fast track designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and myelokathexis, or low white...
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) selected Lighthouse Imaging as the contract manufacturer for the i/Blue Imaging System. Lighthouse is an FDA registered and ISO 13485:2016...
The FDA granted Oncternal Therapeutics’ (NASDAQ:ONCT) TK216 rare pediatric disease designation for the treatment of Ewing sarcoma. Ewing sarcoma is the second most common bone tumor among children and adolescents, with...
Corbus Pharmaceuticals (NASDAQ:CRBP) reported disappointing topline results from its Phase 2b trial of lenabasum for the treatment of cystic fibrosis. Patients were randomized to receive either 5 mg or 20 mg of...
The FDA granted ImmunoGen’s (NASDAQ:IMGN) IMGN632 breakthrough therapy designation for the treatment of relapsed or refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare and aggressive form of...
Hepion Pharmaceuticals (NASDAQ:HEPA) launched AI-POWR, a proprietary AI machine learning platform, which is designed to select novel drug targets, biomarkers, and appropriate patient populations for clinical trials...
The FDA approved Chembio Diagnostics’ (NASDAQ:CEMI) dual path platform (DPP) HIV-syphilis system, a 15-minute test designed to detect HIV Type 1 and 2 antibodies and the bacteria that causes syphilis. The system...
Synthetic Biologics (NYSE American:SYN) reported disappointing results from an interim futility analysis of its Phase 2b clinical study of SYN-010 for the treatment of irritable bowel syndrome with constipation. While...
Otonomy (NASDAQ:OTIC) completed enrollment in its Phase 3 study evaluating OTIVIDEX for the treatment of Meniere’s disease, a disorder of the inner ear that can lead to vertigo and hearing loss. The trial enrolled 149...
Windtree Therapeutics (NASDAQCM:WINT) dosed the first patient in its Phase 2 study evaluating istaroxime in patients with early cardiogenic shock due to heart failure. Cardiogenic shock is a condition where the heart...
Athira Pharma (NASDAQ:ATHA) initiated patient dosing in its Phase 2/3 trial evaluating ATH-1017 for the treatment of mild-to-moderate Alzheimer’s disease. ATH-1017 is a small molecule designed to regenerate brain...
Enlivex Therapeutics (NASDAQ:ENLV) reported positive topline results of an investigator-initiated clinical trial of Allocetra in five COVID-19 patients, three of which were in severe condition and two in critical...
Closely-held Clarigent Health launched Clairity, an app-based listening tool designed to provide clinical decision support to mental health professionals. Clairity uses AI to analyze speech and identify vocal...
Soleno Therapeutics (NASDAQ:SLNO) updated topline results from its Phase 3 trial evaluating diazoxide choline controlled-release (DCCR) tablets for the treatment of Prader-Willi Syndrome (PWS). The randomized, double...
Ocular Therapeutix (NASDAQ:OCUL) dosed the first patients in its Phase 2 trial evaluating OTX-CSI for the treatment of dry eye disease. The trial will enroll some 105 patients who will receive either one of two...
Forte Biosciences (NASDAQ:FBRX) dosed the first patient in its Phase 2 trial evaluating FB-401 for the treatment of atopic dermatitis. FB-401 is a topical mixture comprised primarily of three strains of the commensal...
Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its Phase 2 study evaluating CTP-692 as an adjunctive treatment in patients with schizophrenia. The trial enrolled 325 patients already on a stable course...
Closely-held Field Trip Psychedelics successfully completed GLP synthesis of its psychedelic molecule, FT-104. FT-104 is a new chemical substance designed to be a commercially viable alternative to naturally derived...
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) will host a virtual investor event with key opinion leaders on Oct. 29 at 12:00 pm ET to highlight the potential of the company’s i/Blue...
Closely-held Soricimed Biopharma received $500,000 in funding from the Government of Canada to support the company’s continued research and development work. The Government of Canada provided the repayable contribution...
Closely-held Zucara Therapeutics dosed the first subject in its Phase 1 trial of ZT-01, a once-daily somatostatin inhibitor designed to prevent insulin-induced hypoglycemia. The first, single ascending dose portion...